Lisa Clark PD: EMATTA: Expanding MAT Access through a Team Treatment Approach

EMATTA: Expanding MAT Access through a Team Treatment Approach This project will expand an existing multispecialty opioid-use disorder (OUD) treatment program to provide medication-assisted treatment (MAT) to an additional 240 postpartum and early-parenting women in KY. The project will decrease illicit opioid use and prescription misuse, coordinate MAT and comprehensive OUD treatment, and enhance utilization of ancillary and wraparound services to retain women in treatment and reduce relapse. Goal 1: Increase access to MAT and comprehensive psychosocial services for postpartum and early-parenting women with OUD. 1a) Enroll 240 new clients into the Beyond Birth pro-gram over 3 years (80 per year); 1b) Establish 10 new MAT prescribing treatment groups by the end of year 3; 1c) Obtain 3 new DATA waivers for nurse practitioners (1 by Dec. 2018 and 2 by the end of year 2), and 1d) Provide clients with transportation assistance for 100 MAT treatment visits by the end of year 3. Measured by clinic records. Goal 2: Decrease illicit opioid drug use and prescription misuse among the target population. 2a) Provide comprehensive services for women with OUD resulting in improved treatment outcomes; 2b) Integrate MAT with COR-12, peer support services, and evidenced-based therapies designed to increase retention in treatment and facilitate long-term recovery by the end of year 1. Measured by GPRA metrics for days of self-reported drug use, urine drug screens, pill counts, client retention and clinic service records. Goal 3: Establish a partnership between Beyond Birth (BB) and Chrysalis House (CH) to coordinate services and ensure access to MAT and comprehensive OUD treatment for clients at all levels of SUD and mental health care. 3a) Designate a shared Medical Director between CH and BB by Dec. 2018; 3b) Conduct weekly care coordination meetings comprised of BB and CH project staff and ancillary providers; and 3c) Refer clients and coordinate transitions between CH and BB. Measured by project documentation. Goal 4: Enhance utilization of ancillary and wraparound services for women receiving MAT to reduce relapse risk. 4a) Screen 100% of clients for HCV and initiate treatment for 25% of eligible clients by year 2 of the project; 4b) Discuss the benefits of and offer the use of long-acting contraceptives to 100% of clients within 30 days of enrollment; and 4c) Screen 100% of enrolled clients for co-occurring disorders with standardized tools and provide appropriate intervention as needed. Measured by clinic and medical records. Goal 5: To ensure that the project implementation and evaluation adhere to objectives and facilitate continuous quality improvement (CQI). 5a) Initiate the project within four months of funding award; and 5b) Conduct monthly CQI team meetings comprised of BB and CH project staff, evaluation team members, and ancillary service providers in the first year and bi-monthly meetings in years 2 and 3. Measured by project documentation and reporting.